Skip to main content

Table 2 Summary of pharmacokinetic (PK) parameters of memantine in Study I (administration of the dry syrup as a suspension in water) and Study II (administration of the dry syrup as granules with water)

From: Pharmacokinetics and Bioequivalence of Memantine Tablet and a New Dry Syrup Formulation in Healthy Japanese Males: Two Single-Dose Crossover Studies

  Dry syrup Tablet
Study I (n = 19)
 Cmax (ng/mL) 27.3 (3.89) 27.9 (3.81)
 AUCall (ng h/mL) 1890 (315)b 1950 (288)
 AUCinf (ng h/mL) 2170 (459) 2200 (393)
 Tmax (h)a 6.00 (1.00, 8.00) 6.00 (3.00, 8.00)
 T½ (h) 60.6 (12.5) 60.3 (10.1)
Study II (n = 22)
 Cmax (ng/mL) 27.7 (3.94) 28.5 (3.70)
 AUCall (ng h/mL) 1890 (266)c 1880 (271)
 AUCinf (ng h/mL) 2100 (319)c 2090 (327)
 Tmax (h)a 5.00 (3.00, 8.00) 5.00 (1.00, 12.00)
 T½ (h) 57.1 (7.68)c 57.3 (8.07)
  1. Data are presented as mean (SD)
  2. AUCall area under the concentration–time curve up to the last sampling time, AUCinf area under the concentration–time curve up to infinity, Cmax observed maximum concentration, max maximum, min minimum, SD standard deviation, T½ apparent elimination half-life, Tmax observed time to Cmax
  3. aMedian (min, max)
  4. bn = 18 (number of subjects with reportable AUCall; one subject was excluded due to missing data)
  5. cn = 21 (number of subjects with reportable AUCall, AUCinf, and T½; one subject was excluded due to missing data)